期刊文献+

非小细胞肺癌患者血清TK1水平检测及其与临床特征关系的研究 被引量:4

Relationship between serum thymidine kinase 1 level and clinicopathological features of patients with nonsmall cell lung cancer
下载PDF
导出
摘要 目的探讨血清胸苷激酶1(Thymidine Kinase 1,TK1)水平变化在非小细胞肺癌(Non-Small Cell Lung Cancer,NSCLC)患者临床上的应用价值。方法采用免疫印迹-增强化学发光法检测64例NSCLC患者、31例正常健康查体者血清TK1水平,并对44例NSCLC患者手术前后血清TK1水平变化状况进行比较。结果血清TK1水平与NSCLC患者临床分期有关,与NSCLC患者病理类型、年龄和性别无相关,NSCLC患者血清TK1水平明显高于正常对照组(P〈0.01),NSCLC血清TK1水平Ⅳ期明显高于Ⅲ期,Ⅲ期高于Ⅱ期,Ⅱ期高于Ⅰ期、两两比较差异有统计学意义(P〈0.01~0.05),手术后NSCLC患者血清TK1水平明显低于手术前(P〈0.01)。结论血清TK1表达水平与NSCLC及其临床病理特征密切相关,血清TK1检测对NSCLC患者病情判断、疗效和预后评价有一定的临床意义。 Objective To investigate the changes and its clinical value of serum Thymidine Kinase 1 ( TK1 ) in patients with non-small cell lung cancer(NSCLC). Methods Sensitive chemiluminescence dotblot assay were available to detect the level of serum TK1 in 64 cases of patients with NSCLC and 31 cases of normal control subject, compared with 44 patients with NSCLC pre- and post-operation. Results Serum TK1 was correlated with clinical stage, and not with pathologic types, age and sex of patients with NSCLC, the level of serum TK1 were elevated in all subgroups of patients with NSCLC compared to the controls (P 〈 0. 01 ), the serum TK1 level in stage Ⅳ was higher than that in stage Ⅲ, in stage m it was higher than that in stage Ⅱ , and in stage Ⅱ it was higher than that in stage I (P 〈0.01 ~0.05) , the serum TK1 levels were remarkably reduced in patients with NSCLC after operation( P 〈 0. 01 ). Conclusions This study demonstrates that the expression of serum TK1 have a relationship with clinical pathological feature of patients with NSCLC, it may be act as one index to assess the disease status and the prognosis of NSCLC.
出处 《齐齐哈尔医学院学报》 2014年第17期2499-2500,共2页 Journal of Qiqihar Medical University
关键词 胸苷激酶1 非小细胞肺癌 Thymidine Kinase 1 Non-small cell lung cancer(NSCLC)
  • 相关文献

参考文献7

  • 1Liang QL, Li ZY, Zhou Y, et al. Construction of a Recombinant Eukaryotic Expression vector Containing PHD3 Gene and Its Expression in HepG2 Cells[J]. J Exp Clin Cancer Res,2012,31: 64.
  • 2Mutahir Z, Clausen AR, Andersson KM, et al. Thymidine kinase 1 regulatory fine-tuning through tetramer formation [ J ]. FEBS J, 2013,280(6) :1531-1541.
  • 3Agarwal HK, McElroy CA, Sjuvarsson E, et al. Synthesis of N3- substituted carboranyl thymidine bioconjugates and their evaluation as substrates of recombinant human thymidine kinase 1 [ J ]. Eur J Med Chem,2013,60:456-468.
  • 4Liang QL, Wang BR, Li ZY, et al. Construction of eukaryotic expression vector of TSLC1 gene[J]. Arch Med Sci,2011,7(4) : 579-585.
  • 5Topolcan O, Holubec L Jr. The role of thymidine kinase in cancer diseases[J]. Expert Opin Med Diagn,2008,2(2) :129-141.
  • 6Kuroiwa N, Nakayama M, Fukuda T, et al. Specific recognition of cytosolic thymidine kinase in the human lung tumor by monoclonal antibodies raised against rocombinant human thymidine kinase[ J]. J Immunol Methods,2001,253 (1-2) :1-11.
  • 7Zhang J, Jia Q, Zou S, et al. Thymidine kinase 1 : a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients [ J ]. Oncol Rep, 2006,15(2) :455-461.

同被引文献22

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部